Last reviewed · How we verify
PA1010
At a glance
| Generic name | PA1010 |
|---|---|
| Sponsor | Zhejiang Palo Alto Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of PA1010 in HBV Patients (PHASE1, PHASE2)
- Study of the Safety, Tolerability, Pharmacokinetic Characteristics of PA1010 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PA1010 CI brief — competitive landscape report
- PA1010 updates RSS · CI watch RSS
- Zhejiang Palo Alto Pharmaceuticals, Inc. portfolio CI